AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Short transient receptor potential channel 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q13507

UPID:

TRPC3_HUMAN

Alternative names:

Transient receptor protein 3

Alternative UPACC:

Q13507; A7VJS1; E9PCJ9; O00593; Q15660; Q52M35; Q5G1L5

Background:

Short transient receptor potential channel 3 (TRPC3), also known as Transient receptor protein 3, plays a crucial role in cellular functions by forming a receptor-activated non-selective calcium permeant cation channel. This channel is pivotal in various signaling pathways, activated by receptor tyrosine kinases or G-protein coupled receptors, influencing intracellular calcium levels.

Therapeutic significance:

TRPC3's involvement in Spinocerebellar ataxia 41, a disorder characterized by progressive incoordination and degeneration of the cerebellum, highlights its potential as a therapeutic target. Understanding the role of TRPC3 could open doors to potential therapeutic strategies for treating this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.